Vatorsecurities.se använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.

Corporate Finance

Vator Securities focuses on identifying and financing growth companies as they expand and develop into tomorrow’s market leaders.

read more

About Us

Vator Securities executes on opportunities that accelerate growth for its client companies whilst delivering results to the firm’s sophisticated investor clientele.

read more

On October 7th, Vator Securities arranged the Vator Securities Healthcare Innovation Summit, a digital investor event where you got the opportunity to meet some of the most interesting and innovative companies in Nordic Life Science.

The participating companies were Empros Pharma, Umecrine Cognition, Cyxone, SciBase, Active Biotech, CombiGene, Alligator Bioscience, Immunovia, SenzaGen, Moberg Pharma, Mentice, Magle Chemoswed, Sinfonia Biotherapeutics, Scandion Oncology, AlzeCure Pharma and Sprint Bioscience.

Watch the presentations from the event

Unleashing a paradigm shift in early detection of pancreatic cancer

Advancing into commercial phase, Immunovia has achieved a strong launch of its first product IMMray PanCan-d which was shortly followed by backing of the largest US patient organization Pancreatic Cancer Action Network (PanCAN) and the US National Pancreas Foundation (NPF).

Such support provides real-world commercial third-party validation and should reinforce the capital market’s confidence in the test’s performance and clinical utility offer.

read more

Vator Securities advises Sprint Bioscience on 67 MSEK Rights Issue

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 67,6 million.

Sprint Bioscience develops small-molecule first-in-class drug projects with a focus on oncology. Using fragment-based drug discovery, the company develops drug projects in a time- and resource-efficient way. These are then out-licensed to global drug companies during the preclinical phase.

read more

Vator Securities advises Umecrine Cognition on 35 MSEK Private Placement

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 35,1 million.

Umecrine Cognition is developing golexanolone, a drug candidate with a completely new type of mechanism of action targeting the GABAA receptor in the brain.

read more

Vator Securities advises Plastics Unbound on 30 MSEK Private Placement

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 30,3 million.

Plastics Unbound has successfully completed technical and commercial validation through Tier-1 customer trials and production applications and is now transitioning into larger volume orders.

read more

More News